Better Health for All

Femasys Inc. focuses entirely on women's reproductive health products, including FemBloc for permanent birth control and FemaSeed for infertility, with no reported harmful products.

FemBloc demonstrated a 0% pregnancy rate in clinical trials (n=51) over five years, significantly outperforming the 6% benchmark for surgical sterilization. FemaSeed showed a 26.3% pregnancy rate in trials, compared to 17.5% for IUI, or 24% by subject compared to 6.7% for IUI. For safety, FemBloc reported no serious adverse events in 229 participants over five years, and FemaSeed's adverse events were consistent with intrauterine insemination (IUI). FemaSeed is priced to be a first-line treatment option, significantly less costly than IVF, and FemBloc is positioned as a lower-cost alternative to surgical sterilization. The company conducts prospective, multi-center, unblinded pivotal clinical trials, and its positive data for FemBloc and FemaSeed have been published in peer-reviewed journals.

Fair Money & Economic Opportunity

Femasys Inc. is a biomedical company focused on developing and marketing reproductive health products and medical devices.

Its core business does not involve lending, deposit services, or other financial products for consumers. Consequently, all KPIs related to financial services, such as customer share from underserved segments, pricing fairness, exploitative fees, inclusion initiatives, data accessibility, fair lending compliance, wealth-building outcomes, financial literacy, debt burden, geographic inclusion, and product simplicity, are not applicable to the company's operations. For the year ended December 31, 2024, Femasys reported a net loss of $18,816,628, meaning there were no profits to reinvest in community finance initiatives.

Fair Pay & Worker Respect

Femasys Inc. has no specific regulatory actions, violations, fines, or compliance issues mentioned in the provided articles.

No concrete data is available for living wage coverage, CEO to median employee pay ratio, collective bargaining, safety incident rates, pay equity, worker engagement scores, employee turnover rates, insecure contract share, or health insurance coverage.

Fair Trade & Ethical Sourcing

No specific, quantitative, or sufficiently detailed qualitative evidence was found in the provided articles to assess Femasys Inc. against any of the KPIs for Fair Trade & Ethical Sourcing. While supplier audits are mentioned as occurring 'periodically', this lacks the specific frequency required by the rubric.

Other information regarding supplier processes focuses on quality and regulatory compliance (FDA, ISO, EU MDR, MDSAP) and internal ethical codes, but does not provide data on fair trade certifications, traceability percentages, ethical clauses in contracts, incidents of forced or child labor, or supplier diversity spend.

Honest & Fair Business

Femasys Inc. has a formal whistleblower policy, adopted April 2, 2021, which includes a hotline and online reporting, and offers anonymity.

However, there is no evidence of independent investigation processes. The company also has an anti-corruption policy that explicitly prohibits bribes, kickbacks, and improper payments, including compliance with the FCPA, and provides specific guidelines for gifts and business courtesies. There is no evidence regarding the frequency or effectiveness of training for this policy. No information is available for other KPIs such as regulatory fines, transparency index scores, financial restatements, audit coverage, ESG controversy scores, complaint resolution times, board conflict-free percentage, or third-party verification of ethical claims.

Kind to Animals

No specific information regarding Femasys Inc.'s animal welfare practices, cruelty-free certifications, use of alternative testing methods, or engagement in animal-free research and development was found in the provided articles. The 2024 Annual Report () explicitly states that information on these topics is not applicable or not found within the report.

, a regulatory filing, also contains no relevant data.

No War, No Weapons

Femasys Inc. is a biomedical company focused on women's reproductive health, developing products for contraception, fertility, and diagnostics.

The company's activities include medical device manufacturing, clinical trials, and marketing of these products. The provided articles confirm that the company's mission and activities are entirely focused on women's health, with no mention of defense-related or conflict-related business. Therefore, all KPIs related to arms, defense, dual-use technologies, or conflict-zone activities are not applicable to Femasys Inc.'s core operations.

Planet-Friendly Business

Femasys Inc. lacks publicly available data for all specified environmental performance metrics. The provided articles do not disclose information regarding Scope 1, 2, and 3 emissions, science-based targets, renewable energy use, water consumption, green building certifications, waste diversion rates, lifecycle impact analyses, recycled material usage, carbon offset quality, climate-positive initiatives, supply chain climate transparency, biodiversity efforts, deforestation policies, environmental compliance violations, environmental impact assessments, net-zero targets, TCFD alignment, climate scenario analysis, stranded asset transparency, water sourcing from stressed basins, packaging CO2 reduction, climate justice initiatives, just transition programs, or climate adaptation financing.

While one product, FemVue® MINI, is described as 'eco-friendly' and having an 'eco-conscious form factor,' no quantitative data is provided to support specific environmental performance for any KPI.

Respect for Cultures & Communities

No specific, concrete data points were found in the provided articles for any of the KPIs related to 'Respect for Cultures & Communities'.

The articles either did not mention these aspects or explicitly stated that data was not available or not mentioned, indicating significant data gaps regarding community engagement and cultural sensitivity.

Safe & Smart Tech

Femasys Inc. has reported no material cybersecurity threats or incidents to date, and no incidents of unauthorized data use, indicating a standard level of data security.

The company maintains commercially reasonable safeguards to protect personal information and continuously monitors for unauthorized access. Femasys has a strong record of regulatory compliance and certifications, holding ISO 13485 Quality System Certification and MDSAP Certificates of Registration. It successfully completed its annual MDSAP surveillance audit on October 03, 2023, with no nonconformances. Furthermore, Femasys completed the EU Medical Device Regulation (MDR) final audit on October 26, 2023, with zero nonconformances and no findings, and received CE Mark certification for four products (FemaSeed®, FemVue®, FemCerv®, and FemCath®) as of June 20, 2024. The company's privacy policy, last updated March 18, 2024, outlines user rights for updating information and opting out of emails, and states that data is retained only as long as necessary to fulfill purposes, comply with business requirements, and legal obligations. The company has processes in place to assess, identify, and manage risks, including third-party assessments and testing for vulnerabilities and security. Users can update or change their information by emailing the company, and specific opt-out mechanisms are provided for email preferences and cookie management.